The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...
Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback